Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Gliosarcoma 2Glioblastoma 2Central Nervous System Neoplasms 2Breast Neoplasms 2Uveal Melanoma 1Oligodendroglioma 1Melanoma 1Lung Neoplasms 1Glioma 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Astrocytoma 1

Interventions

Trastuzumab 350Paclitaxel 334Cyclophosphamide 315Docetaxel 291Capecitabine 181Doxorubicin 180Letrozole 166Tamoxifen 145Bevacizumab 124Fulvestrant 118Carboplatin 118exemestane 111Lapatinib 111Anastrozole 111Radiotherapy 105Epirubicin 104Gemcitabine 97palbociclib 84Exercise 78Vinorelbine 77Fluorouracil 77Surveys and Questionnaires 71pertuzumab 67Filgrastim 64Albumin-Bound Paclitaxel 64eribulin 55Magnetic Resonance Spectroscopy 55Everolimus 52Blood Specimen Collection 51Zoledronic Acid 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Breast Neoplasms × NSC 366140 × Clear all
NCT00003041 2013-01-31

Pyrazoloacridine in Treating Women With Refractory Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 2 Completed
Breast

Breast Neoplasms

NCT00002585 2012-03-12

Pyrazoloacridine in Treating Women With Metastatic Breast Cancer

Barbara Ann Karmanos Cancer Institute

Phase 2 Completed
20 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡